A potent and selective RET inhibitor with efficacy in RET-driven mouse models of medullary thyroid carcinoma and lung adenocarcinoma

被引：0
|
作者：
Watson, Mandy
Small, Helen
Acton, Ben
Begum, Habiba
Hitchin, Samantha
Jordan, Allan
Kelly, Paul
Newton, Rebecca
Waddell, Ian
Paris, Gina
Ogilvie, Donald
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2092
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Delivery of a potent, selective, and efficacious RET inhibitor for the treatment of RET-driven lung adenocarcinoma
    Watson, Mandy
    Newton, Rebecca
    Acton, Ben
    Small, Helen
    Begum, Habiba
    Hitchin, Samantha
    Kelly, Paul
    Ogilvie, Donald
    Waddell, Ian
    Jordan, Allan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [2] The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
    Ezra Y. Rosen
    Helen H. Won
    Youyun Zheng
    Emiliano Cocco
    Duygu Selcuklu
    Yixiao Gong
    Noah D. Friedman
    Ino de Bruijn
    Onur Sumer
    Craig M. Bielski
    Casey Savin
    Caitlin Bourque
    Christina Falcon
    Nikeysha Clarke
    Xiaohong Jing
    Fanli Meng
    Catherine Zimel
    Sophie Shifman
    Srushti Kittane
    Fan Wu
    Marc Ladanyi
    Kevin Ebata
    Jennifer Kherani
    Barbara J. Brandhuber
    James Fagin
    Eric J. Sherman
    Natasha Rekhtman
    Michael F. Berger
    Maurizio Scaltriti
    David M. Hyman
    Barry S. Taylor
    Alexander Drilon
    Nature Communications, 13
  • [3] The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
    Rosen, Ezra Y.
    Won, Helen H.
    Zheng, Youyun
    Cocco, Emiliano
    Selcuklu, Duygu
    Gong, Yixiao
    Friedman, Noah D.
    de Bruijn, Ino
    Sumer, Onur
    Bielski, Craig M.
    Savin, Casey
    Bourque, Caitlin
    Falcon, Christina
    Clarke, Nikeysha
    Jing, Xiaohong
    Meng, Fanli
    Zimel, Catherine
    Shifman, Sophie
    Kittane, Srusthi
    Wu, Fan
    Ladanyi, Marc
    Ebata, Kevin
    Kherani, Jennifer
    Brandhuber, Barbara J.
    Fagin, James
    Sherman, Eric J.
    Rekhtman, Natasha
    Berger, Michael F.
    Scaltriti, Maurizio
    Hyman, David M.
    Taylor, Barry S.
    Drilon, Alexander
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [4] Novel therapeutic agents for RET-driven cancers, which is highly potent and selective inhibitor to RET kinase
    Li, Hua
    Jo, SeoHyun
    Do, Woomi
    Kim, Hyunkyung
    Kim, Hwan
    Seo, Kyung-ah
    Oh, Ji-hoon
    Choi, Jieun
    Ahn, Jaeyoung
    Son, Jung Beom
    Kim, Nam Doo
    CANCER RESEARCH, 2019, 79 (13)
  • [5] BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers
    Rahal, Rami
    Maynard, Michelle
    Hu, Wei
    Brubaker, Jason
    Cao, Qiongfang
    Kim, Joseph L.
    Sheets, Michael P.
    Wilson, Douglas P.
    Wilson, Kevin J.
    DiPietro, Lucian
    Fleming, Paul
    LaBranche, Timothy P.
    Wolf, Beni
    Guzi, Timothy
    Lengauer, Christoph
    Evans, Erica K.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [6] TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
    Drilon, A.
    Rogers, E.
    Zhai, D.
    Deng, W.
    Zhang, X.
    Lee, D.
    Ung, J.
    Whitten, J.
    Zhang, H.
    Liu, J.
    Hu, T.
    Zhuang, H.
    Lu, Y.
    Huang, Z.
    Graber, A.
    Zimmerman, Z.
    Xin, R.
    Cui, J. J.
    Subbiah, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 190 - +
  • [7] BLU-667: A highly selective RET inhibitor to target RET-driven NSCLC
    Rahal, Rami
    Maynard, Michelle
    Hu, Wei
    Brubaker, Jason
    Cao, Qiangfang
    Kim, Joseph L.
    Sheets, Michael P.
    Wilson, Douglas P.
    Wilson, Kevin J.
    DiPietro, Lucian
    LaBranche, Timothy
    Wolf, Beni
    Guzi, Timothy
    Lengauer, Christoph
    Evans, Erica K.
    CLINICAL CANCER RESEARCH, 2018, 24 (17)
  • [8] A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo
    Samadi, Abbas K.
    Mukerji, Ridhwi
    Shah, Anuj
    Timmermann, Barbara N.
    Cohen, Mark S.
    SURGERY, 2010, 148 (06) : 1228 - 1236
  • [9] NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models
    Ardini, Elena
    Banfi, Patrizia
    Avanzi, Nilla
    Ciomei, Marina
    Polucci, Paolo
    Cirla, Alessandra
    Ermoli, Antonella
    Motto, Ilaria
    Casale, Elena
    Canevari, Giulia
    Cristiani, Cinzia
    Troiani, Sonia
    Sirtori, Federico Riccardi
    Amboldi, Nadia
    Ballinari, Dario
    Caprera, Francesco
    Felder, Eduard
    Galvani, Arturo
    Donati, Daniele
    Isacchi, Antonella
    Menichincheri, Maria
    CANCER RESEARCH, 2017, 77
  • [10] Characterization of a Novel, Highly Potent and Selective RET Inhibitor with Antitumor Efficacy in RET Dependent Models
    Ardini, E.
    Amboldil, N.
    Avanzi, N.
    Banfi, P.
    Cristiani, C.
    Donati, D.
    Galvani, A.
    Isacchi, A.
    Pesenti, E.
    Menichincheri, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 94 - 95
12345